Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli (OVERCOME)

Completed · Phase 3 · Has a placebo group

Conditions studied: Pneumonia, Blood Stream Infection

In brief

Approximately 444 subjects who are greater than or equal to 18 to 95 years of age, are non-pregnant, and are in the inpatient setting of one of the study sites will be evaluated to treatment efficacy. Analysis will include subjects with bloodstream infection (BSI) or pneumonia due to at least one of the following gram-negative bacilli organisms: Acinetobacter baumannii, Klebsiella spp, Escherichia coli, Enterobacter spp. and/or Pseudomonas aeruginosa that demonstrates in vitro non-susceptibility defined as extensively drug-resistant Gram-negative bacilli (XDR-GNB) which includes XDR-AB, XDR-PA and CRE. If a subject has both BSI and pneumonia at the time of study enrollment, they will be included as a subject with pneumonia. Objectives: Primary: •Determine whether the treatment regimen of Colistimethate sodium (colistin) combined with a carbapenem (imipenem or meropenem) is associated with a decreased risk for mortality compared to colistin alone for subjects with bloodstream infection (BSI) and/or pneumonia due to XDR-GNB. Secondary: •Determine what treatment regimen (colistin monotherapy or colistin combined with a carbapenem (imipenem or meropenem) is more likely to reduce the emergence of colistin resistance among XDR-GNB isolates during therapy.

Key facts

Study ID: NCT01597973
Run by: University of Michigan
People needed: 467
Starts: 2012-10-06
Expected to finish: 2020-08-09
Last updated by the study team: 2022-11-14

Who can join

Age: 18 and older, up to 95. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Hospitalized Adults (> 18 years to 95 years of age), at one of the study sites.
Diagnosis of BSI and/or pneumonia due to a preliminary result of gram-negative non-lactose fermenter that is oxidase negative; or a final results of XDR-A. baumannii; carbapenem-resistant Enterobacteriaceae; or XDR- P. aeruginosa and/or patients with suspected BSI and/or HAP (hospital acquired pneumonia) and who have had a prior history (within last 6 months) of XDR-GNB that was susceptible to colistin.
o If final results do not indicate that the pathogen is an XDR-GNB, and identifies alternative treatment options, the patient would be eligible for the study if the subject is allergic to all the alternative treatment options.
Patients with polymicrobial respiratory or blood infections, including XDR-GNB and one or more pathogens, will be included in the study, as long as the XDR-GNB is determined to be a true pathogen (AB, CRE or PA). Other pathogens will be treated with antimicrobial agents as determined by the treating physician.
If more than one XDR-GNB study pathogens is identified as a study pathogen causing BSI and/or pneumonia, then the first study pathogen recovered will be considered as the primary study pathogen. If more than one study pathogen is recovered from the same culture, then the infection will be categorized as being caused by multiple study pathogens.
Patients with a life expectancy of > 24 hours
Signed written informed consent and HIPAA Authorization form (US sites)

You may not qualify if…

Female patients who are pregnant
Female patients who are nursing
Patients who are prisoners
Patients who are less than 18 years of age or greater than or equal to 96 years of age
Patients with neutropenia (WBC < 500 cells/mm3)
The presence of any of the following known clinical syndromes involving XDR-GNB as a pathogen which necessitate durations of antimicrobial therapies greater than 14 days: endocarditis, osteomyelitis, prosthetic joint infections, meningitis and/or other central nervous system infections.
Patients receiving valproic acid (with or without a known seizure disorder).
Patients who received 72 hours or more of polymyxin treatment (intravenous or inhaled [pneumonia]) within 96 hours of enrollment.
Patients who have end-stage renal disease requiring hemodialysis, will be excluded from evaluation pertaining to nephrotoxicity in the per protocol population.
Patients with known Type 1 or other severe drug allergy to either of the study drugs or to β-lactams.

Where it is running

Jackson Memorial Hospital-Jackson Health System — Miami, Florida, United States
Wayne State University — Detroit, Michigan, United States
Henry Ford Health System — Detroit, Michigan, United States
Beaumont Health System — Royal Oak, Michigan, United States
Mount Sinai Hospital — New York, New York, United States
The Ohio State University Wexner Medical Center — Columbus, Ohio, United States
University Multiprofile Hospital for Active Treatment and Emergency Medicine "N.I. Pirogov" — Sofia, Bulgaria
University Hospital of Heraklion — Crete, Crete, Greece
Evangelismos General Hospital of Athens — Athens, Greece
General Hospital of Athens "Laiko" 1st Department of Medicine — Athens, Greece
Attikon University General Hospital of Athens — Athens, Greece
Hippokration General Hospital of Thessaloniki — Thessaloniki, Greece
Assaf Harofeh Medical Center — Ẕerifin, Beer Yaakov, Israel
Rabin Medical Centre, Beilinson Campus — Petah Tikva, Central District, Israel
Rambam Health Care Campus — Haifa, Israel
Tel-Aviv Sourasky Medical Center — Tel Aviv, Israel
Universita della Campania 'Luigi Vanvitelli' — Naples, Italy
Chang Gung Memorial Hospital — Taoyuan, Kwei-San, Taiwan
Siriraj Hospital — Bangkoknoi, Bangkok, Thailand

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.